UPDATE: Looks like the traditional press are catching on - take a look at this article on CNNMoney.
At the recent 2007 Congress of the International MYOPAIN Society (a nonprofit organization of medical professionals dedicated to “the promotion of information about soft-tissue pain disorders like myofascial pain syndrome and fibromyalgia syndrome”), showed some promising results in a study that compared Cymbalta to placebo in fibro pain. Patients both with and without depression were included in the study, which (along with 4 others) prompted Cymbalta’s maker Eli Lilly to submit a supplemental application to the FDA for the use of Cymbalta in fibro treatments (click here for Eli Lilly’s press release on the subject).
Cymbalta is an antidepressant - specifically, it’s characterized as a “dual re-uptake inhibitor of serotonin and norepinephrine.” (See this page from Wikipedia for more information on the drug, generic name duloxetine.) This isn’t the first time Cymbalta’s been the subject of fibro treatment studies; this article from Medical News Today discusses a similar study from 2004 presented at an Annual Meeting of the American College of Rheumatology.
If you liked my post, feel free to subscribe to my rss feeds
BlogoSquare